Investigation of Flurbiprofen Pharmacokinetics in Rats Following Dermal Administration of Optimized Cyclodextrin-Based Nanogel.

Purpose: The main purpose of this study was to optimize a cyclodextrin-based nanogel of flurbiprofen (FP) for prolonged dermal administration and evaluate its stability, in vitro release, ex vivo skin permeation, and in vivo pharmacokinetic profile.

Methods: The nanogels were prepared via emulsification/solvent evaporation process and optimized through design of experiments. Optimal formulation was characterized via particle size (PS), polydispersity index (PDI), zeta potential (ZP), differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD), solubility, stability, in vitro release/ex vivo permeation studies and mathematical modeling, and pharmacokinetic studies conducted in rats. Results were compared to HPMC-based gel that was not nano-sized (i.e.FP-HPMC gel).

Results: The PS, PDI and ZP values of optimal FP-loaded nanogel were 295.5nm, 0.361 and -31.9mV, respectively and it was stable for 12 months. In in vitro release studies, the flux from the optimal FP-loaded nanogel (96.3µg/hcm) was three times slower (i.e.more controlled) than that of the FP-HPMC gel (287µg/hcm); the permeability coefficient of the nanogel (0.015cm/h) was slightly less than that of FP-HPMC gel (0.046cm/h). Rat skin studies showed FP-loaded nanogel provided higher drug retention in the skin, compared to FP-HPMC gel. Mathematical modeling from rat skin permeation showed the Hixson-Crowell model was the best fitting model for FP-loaded nanogel, suggesting surface area of the nanogel is changing during the release process. In rat pharmacokinetic studies, the FB-loaded nanogel exhibited prolonged and flatter plasma profile than the FP-HPMC gel, consistent with the higher drug retention in the skin.

Conclusion: The optimized nanogel provided prolonged drug permeation and more sustained pharmacokinetic performance compared to FP-HPMC gel.